Analysis Group Expert Publishes Article on Value vs. Budget in Drug Pricing

October 10, 2017

In an article published on Law360.com, Analysis Group Vice President Noam Kirson discusses the difference between value and budget impact – issues that he says are often conflated in the current public policy discourse around prescription drug prices and spending. In “Consider Value Vs. Budget Impact in Mass. Drug Prices,” Dr. Kirson discusses how innovative therapies can increase costs for the healthcare system while still offering considerable value. He reviews various challenges and considerations in the current policy debate on drug pricing and their relation to the potential tension between value and budget impact. Dr. Kirson contends that a focus on price alone, as opposed to the underlying value of prescription drugs, is at the root of many controversies surrounding high prescription drug prices, nationally as well as within the state of Massachusetts. 

Read the Law360 article